Related Experiment Video
Updated: Apr 29, 2026
Development of Combinatorial Therapeutics for Spinal Cord Injury using Stem Cell Delivery
Published on: June 7, 2024
Nanovector-mediated drug delivery for spinal cord injury treatment
Ilaria Caron1, Simonetta Papa, Filippo Rossi
1Department of Neuroscience, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
Abstract:
Spinal cord injury (SCI) is the result of a traumatic primary event followed by a so-called secondary injury, which is characterized by a large spectrum of biochemical cellular pathways able to spread the lesion, worsening neurologic recovery. A growing number of potential therapeutic interventions to counteract different neurodegenerative mechanisms of SCI have been proposed, but they did not show relevant efficacy when translated as clinical treatments. Different reasons could explain these disappointing results: on one side the multifactorial evolution of SCI after the primary injury that limits the beneficial effect of just one targeted treatment and, on the other, the restricted access of pharmacological therapies to the spinal cord. For these reasons, recently, a growing interest has been shown in the development of alternative delivery strategies to administer drugs and/or biological/cellular therapies into the spine (hydrogel and nanoparticles).
Insights
Spinal cord injury (SCI) involves secondary injury pathways that worsen recovery. New drug delivery methods like hydrogels and nanoparticles show promise for treating SCI effectively.
Area of Science:
- Neuroscience
- Biomedical Engineering
- Regenerative Medicine
Background:
- Spinal cord injury (SCI) involves primary trauma followed by secondary injury cascades.
- Secondary injury mechanisms involve complex biochemical pathways that exacerbate damage and impede neurological recovery.
- Current therapeutic interventions for SCI have shown limited clinical efficacy due to the multifactorial nature of the injury and poor drug penetration.
Purpose of the Study:
- To explore advanced therapeutic strategies for spinal cord injury (SCI).
- To address the limitations of conventional treatments in accessing the spinal cord.
- To investigate novel drug and cell delivery systems for SCI.
Main Methods:
- Review of existing literature on SCI pathophysiology and treatment challenges.
- Exploration of emerging drug delivery technologies, including hydrogels and nanoparticles.
- Analysis of the potential of these advanced systems for delivering therapeutics to the spinal cord.
Main Results:
- The multifactorial nature of SCI limits the efficacy of single-target treatments.
- Restricted access of pharmacological agents to the spinal cord is a major therapeutic hurdle.
- Hydrogels and nanoparticles offer promising alternative delivery strategies for SCI therapeutics.
Conclusions:
- Novel delivery systems are crucial for overcoming current therapeutic limitations in SCI.
- Hydrogels and nanoparticles represent promising avenues for enhanced drug and cell delivery to the spinal cord.
- Further research into these delivery strategies could significantly improve outcomes for spinal cord injury patients.
